Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

1.75
-1.4200-44.79%
Post-market: 1.750.00000.00%19:59 EDT
Volume:112.36M
Turnover:199.07M
Market Cap:584.39M
PE:-1.36
High:1.99
Open:1.94
Low:1.65
Close:3.17
Loading ...

Sector Update: Health Care Stocks Softer Friday Afternoon

MT Newswires Live
·
Yesterday

Iovance Biotherapeutics Stock Sinks 46%. Here's Why the Biotech Is Tumbling. -- Barrons.com

Dow Jones
·
09 May

Iovance Biotherapeutics Shares Drop After Wider-Than-Expected 1Q Loss

Dow Jones
·
09 May

Stock Track | Iovance Biotherapeutics Plummets 39.43% After Q1 Earnings Miss and Slashed Revenue Guidance

Stock Track
·
09 May

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

MT Newswires Live
·
09 May

Wall Street Set to Open Higher Friday as Investors Calmed by Trade Talks

MT Newswires Live
·
09 May

US Equity Futures Higher as Trump Considers 80% China Tariffs

MT Newswires Live
·
09 May

Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20

MT Newswires Live
·
09 May

Iovance Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
09 May

Iovance Biotherapeutics Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
09 May

Stock Track | Iovance Biotherapeutics Plunges 32% Pre-Market After Q1 Earnings Miss and Lowered Guidance

Stock Track
·
09 May

Stock Track | Iovance Biotherapeutics Plummets 38.49% After Hours on Q1 Earnings Miss and Lowered Guidance

Stock Track
·
09 May

Iovance Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Stock Track | Iovance Biotherapeutics Plunges 40% After-Hours on Q1 Earnings Miss and Lowered Revenue Guidance

Stock Track
·
09 May

Stock Track | Iovance Biotherapeutics Plummets 40% After Hours on Disappointing Q1 Results and Lowered Guidance

Stock Track
·
09 May

Iovance Biotherapeutics Extends Drop After Results, Last Down 38.5% in Extended Trading

THOMSON REUTERS
·
09 May

Iovance Biotherapeutics Q1 EPS $(0.36) Misses $(0.24) Estimate, Sales $49.32M Miss $81.70M Estimate

Benzinga
·
09 May

BRIEF-Iovance Biotherapeutics Q1 Operating Income USD -121.221 Million

Reuters
·
09 May

Iovance Biotherapeutics Inc: FY25 Total Product Revenue Guidance Revised to $250M-$300M

THOMSON REUTERS
·
09 May

Iovance Biotherapeutics Q1 EPS USD -0.36

THOMSON REUTERS
·
09 May